In	B:C1515655
vivo	I:C1515655
Distribution	O
and	O
Clearance	O
of	O
Purified	O
Capsular	I:C0982056
Polysaccharide	I:C0982056
from	O
Burkholderia	O
pseudomallei	I:C0033819
in	O
a	O
Murine	O
Model	I:C0012644
.	O

In	O
vivo	I:C1515655
Distribution	O
and	O
Clearance	O
of	O
Purified	B:C0982056
Capsular	I:C0982056
Polysaccharide	I:C0982056
from	O
Burkholderia	O
pseudomallei	I:C0033819
in	O
a	O
Murine	O
Model	I:C0012644
.	O

In	O
vivo	I:C1515655
Distribution	O
and	O
Clearance	O
of	O
Purified	O
Capsular	I:C0982056
Polysaccharide	I:C0982056
from	O
Burkholderia	B:C0033819
pseudomallei	I:C0033819
in	O
a	O
Murine	O
Model	I:C0012644
.	O

In	O
vivo	I:C1515655
Distribution	O
and	O
Clearance	O
of	O
Purified	O
Capsular	I:C0982056
Polysaccharide	I:C0982056
from	O
Burkholderia	O
pseudomallei	I:C0033819
in	O
a	O
Murine	B:C0012644
Model	I:C0012644
.	O

Burkholderia	B:C0033819
pseudomallei	I:C0033819
is	O
the	O
causative	O
agent	I:C0449411
of	O
melioidosis	O
,	O
a	O
severe	O
infection	O
prominent	O
in	O
northern	O
Australia	O
and	O
Southeast	O
Asia	I:C0003983
.	O

Burkholderia	O
pseudomallei	I:C0033819
is	O
the	O
causative	B:C0449411
agent	I:C0449411
of	O
melioidosis	O
,	O
a	O
severe	O
infection	O
prominent	O
in	O
northern	O
Australia	O
and	O
Southeast	O
Asia	I:C0003983
.	O

Burkholderia	O
pseudomallei	I:C0033819
is	O
the	O
causative	O
agent	I:C0449411
of	O
melioidosis	B:C0025229
,	O
a	O
severe	O
infection	O
prominent	O
in	O
northern	O
Australia	O
and	O
Southeast	O
Asia	I:C0003983
.	O

Burkholderia	O
pseudomallei	I:C0033819
is	O
the	O
causative	O
agent	I:C0449411
of	O
melioidosis	O
,	O
a	O
severe	O
infection	B:C3714514
prominent	O
in	O
northern	O
Australia	O
and	O
Southeast	O
Asia	I:C0003983
.	O

Burkholderia	O
pseudomallei	I:C0033819
is	O
the	O
causative	O
agent	I:C0449411
of	O
melioidosis	O
,	O
a	O
severe	O
infection	O
prominent	O
in	O
northern	O
Australia	O
and	O
Southeast	B:C0003983
Asia	I:C0003983
.	O

The	O
"	O
gold	O
standard	O
"	O
for	O
melioidosis	B:C0025229
diagnosis	O
is	O
bacterial	O
isolation	I:C0430402
,	O
which	O
takes	O
several	O
days	I:C3845714
to	O
complete	O
.	O

The	O
"	O
gold	O
standard	O
"	O
for	O
melioidosis	O
diagnosis	B:C0430022
is	O
bacterial	O
isolation	I:C0430402
,	O
which	O
takes	O
several	O
days	I:C3845714
to	O
complete	O
.	O

The	O
"	O
gold	O
standard	O
"	O
for	O
melioidosis	O
diagnosis	O
is	O
bacterial	B:C0430402
isolation	I:C0430402
,	O
which	O
takes	O
several	O
days	I:C3845714
to	O
complete	O
.	O

The	O
"	O
gold	O
standard	O
"	O
for	O
melioidosis	O
diagnosis	O
is	O
bacterial	O
isolation	I:C0430402
,	O
which	O
takes	O
several	B:C3845714
days	I:C3845714
to	O
complete	O
.	O

The	O
resulting	O
delay	O
in	O
diagnosis	B:C0430022
leads	O
to	O
delayed	O
treatments	O
,	O
which	O
could	O
result	O
in	O
death	O
.	O

The	O
resulting	O
delay	O
in	O
diagnosis	O
leads	O
to	O
delayed	O
treatments	O
,	O
which	O
could	O
result	O
in	O
death	B:C1306577
.	O

In	O
an	O
attempt	O
to	O
develop	O
better	O
methods	B:C0430022
for	O
early	O
diagnosis	I:C0596473
of	O
melioidosis	O
,	O
B.	O
pseudomallei	I:C0033819
capsular	O
polysaccharide	I:C0982056
(	O
capsular	O
polysaccharide	I:C0982056
)	O
was	O
identified	O
as	O
an	O
important	O
diagnostic	O
biomarker	O
.	O

In	O
an	O
attempt	O
to	O
develop	O
better	O
methods	O
for	O
early	B:C0596473
diagnosis	I:C0596473
of	O
melioidosis	O
,	O
B.	O
pseudomallei	I:C0033819
capsular	O
polysaccharide	I:C0982056
(	O
capsular	O
polysaccharide	I:C0982056
)	O
was	O
identified	O
as	O
an	O
important	O
diagnostic	O
biomarker	O
.	O

In	O
an	O
attempt	O
to	O
develop	O
better	O
methods	O
for	O
early	O
diagnosis	I:C0596473
of	O
melioidosis	B:C0025229
,	O
B.	O
pseudomallei	I:C0033819
capsular	O
polysaccharide	I:C0982056
(	O
capsular	O
polysaccharide	I:C0982056
)	O
was	O
identified	O
as	O
an	O
important	O
diagnostic	O
biomarker	O
.	O

In	O
an	O
attempt	O
to	O
develop	O
better	O
methods	O
for	O
early	O
diagnosis	I:C0596473
of	O
melioidosis	O
,	O
B.	B:C0033819
pseudomallei	I:C0033819
capsular	O
polysaccharide	I:C0982056
(	O
capsular	O
polysaccharide	I:C0982056
)	O
was	O
identified	O
as	O
an	O
important	O
diagnostic	O
biomarker	O
.	O

In	O
an	O
attempt	O
to	O
develop	O
better	O
methods	O
for	O
early	O
diagnosis	I:C0596473
of	O
melioidosis	O
,	O
B.	O
pseudomallei	I:C0033819
capsular	B:C0982056
polysaccharide	I:C0982056
(	O
capsular	O
polysaccharide	I:C0982056
)	O
was	O
identified	O
as	O
an	O
important	O
diagnostic	O
biomarker	O
.	O

In	O
an	O
attempt	O
to	O
develop	O
better	O
methods	O
for	O
early	O
diagnosis	I:C0596473
of	O
melioidosis	O
,	O
B.	O
pseudomallei	I:C0033819
capsular	O
polysaccharide	I:C0982056
(	O
capsular	B:C0982056
polysaccharide	I:C0982056
)	O
was	O
identified	O
as	O
an	O
important	O
diagnostic	O
biomarker	O
.	O

In	O
an	O
attempt	O
to	O
develop	O
better	O
methods	O
for	O
early	O
diagnosis	I:C0596473
of	O
melioidosis	O
,	O
B.	O
pseudomallei	I:C0033819
capsular	O
polysaccharide	I:C0982056
(	O
capsular	O
polysaccharide	I:C0982056
)	O
was	O
identified	O
as	O
an	O
important	O
diagnostic	O
biomarker	B:C0005516
.	O

A	O
rapid	O
lateral	O
flow	O
immunoassay	B:C0020980
utilizing	O
capsular	O
polysaccharide	I:C0982056
-	O
specific	O
monoclonal	O
antibody	I:C0003250
was	O
developed	O
and	O
tested	O
in	O
endemic	O
regions	I:C0017446
worldwide	O
.	O

A	O
rapid	O
lateral	O
flow	O
immunoassay	O
utilizing	O
capsular	B:C0982056
polysaccharide	I:C0982056
-	O
specific	O
monoclonal	O
antibody	I:C0003250
was	O
developed	O
and	O
tested	O
in	O
endemic	O
regions	I:C0017446
worldwide	O
.	O

A	O
rapid	O
lateral	O
flow	O
immunoassay	O
utilizing	O
capsular	O
polysaccharide	I:C0982056
-	O
specific	O
monoclonal	B:C0003250
antibody	I:C0003250
was	O
developed	O
and	O
tested	O
in	O
endemic	O
regions	I:C0017446
worldwide	O
.	O

A	O
rapid	O
lateral	O
flow	O
immunoassay	O
utilizing	O
capsular	O
polysaccharide	I:C0982056
-	O
specific	O
monoclonal	O
antibody	I:C0003250
was	O
developed	O
and	O
tested	O
in	O
endemic	B:C0017446
regions	I:C0017446
worldwide	O
.	O

A	O
rapid	O
lateral	O
flow	O
immunoassay	O
utilizing	O
capsular	O
polysaccharide	I:C0982056
-	O
specific	O
monoclonal	O
antibody	I:C0003250
was	O
developed	O
and	O
tested	O
in	O
endemic	O
regions	I:C0017446
worldwide	B:C0332464
.	O

However	O
,	O
the	O
in	B:C1515655
vivo	I:C1515655
fate	O
and	O
clearance	O
of	O
capsular	O
polysaccharide	I:C0982056
has	O
never	O
been	O
thoroughly	O
investigated	O
.	O

However	O
,	O
the	O
in	O
vivo	I:C1515655
fate	O
and	O
clearance	O
of	O
capsular	B:C0982056
polysaccharide	I:C0982056
has	O
never	O
been	O
thoroughly	O
investigated	O
.	O

Here	O
,	O
we	O
injected	B:C0025929
mice	I:C0025929
with	O
purified	O
CPS	I:C0982056
intravenously	O
and	O
determined	O
capsular	O
polysaccharide	I:C0982056
concentrations	O
in	O
serum	O
,	O
urine	O
,	O
and	O
major	O
organs	O
at	O
various	O
intervals	O
.	O

Here	O
,	O
we	O
injected	O
mice	I:C0025929
with	O
purified	B:C0982056
CPS	I:C0982056
intravenously	O
and	O
determined	O
capsular	O
polysaccharide	I:C0982056
concentrations	O
in	O
serum	O
,	O
urine	O
,	O
and	O
major	O
organs	O
at	O
various	O
intervals	O
.	O

Here	O
,	O
we	O
injected	O
mice	I:C0025929
with	O
purified	O
CPS	I:C0982056
intravenously	B:C0348016
and	O
determined	O
capsular	O
polysaccharide	I:C0982056
concentrations	O
in	O
serum	O
,	O
urine	O
,	O
and	O
major	O
organs	O
at	O
various	O
intervals	O
.	O

Here	O
,	O
we	O
injected	O
mice	I:C0025929
with	O
purified	O
CPS	I:C0982056
intravenously	O
and	O
determined	O
capsular	B:C0982056
polysaccharide	I:C0982056
concentrations	O
in	O
serum	O
,	O
urine	O
,	O
and	O
major	O
organs	O
at	O
various	O
intervals	O
.	O

Here	O
,	O
we	O
injected	O
mice	I:C0025929
with	O
purified	O
CPS	I:C0982056
intravenously	O
and	O
determined	O
capsular	O
polysaccharide	I:C0982056
concentrations	O
in	O
serum	B:C0229671
,	O
urine	O
,	O
and	O
major	O
organs	O
at	O
various	O
intervals	O
.	O

Here	O
,	O
we	O
injected	O
mice	I:C0025929
with	O
purified	O
CPS	I:C0982056
intravenously	O
and	O
determined	O
capsular	O
polysaccharide	I:C0982056
concentrations	O
in	O
serum	O
,	O
urine	B:C0042036
,	O
and	O
major	O
organs	O
at	O
various	O
intervals	O
.	O

Here	O
,	O
we	O
injected	O
mice	I:C0025929
with	O
purified	O
CPS	I:C0982056
intravenously	O
and	O
determined	O
capsular	O
polysaccharide	I:C0982056
concentrations	O
in	O
serum	O
,	O
urine	O
,	O
and	O
major	O
organs	B:C0178784
at	O
various	O
intervals	O
.	O

The	O
results	O
indicate	O
that	O
capsular	B:C0982056
polysaccharide	I:C0982056
is	O
predominantly	O
eliminated	O
through	O
urine	O
and	O
no	O
capsular	O
polysaccharide	I:C0982056
accumulation	O
occurs	O
in	O
the	O
major	O
organs	O
.	O

The	O
results	O
indicate	O
that	O
capsular	O
polysaccharide	I:C0982056
is	O
predominantly	O
eliminated	O
through	O
urine	B:C0042036
and	O
no	O
capsular	O
polysaccharide	I:C0982056
accumulation	O
occurs	O
in	O
the	O
major	O
organs	O
.	O

The	O
results	O
indicate	O
that	O
capsular	O
polysaccharide	I:C0982056
is	O
predominantly	O
eliminated	O
through	O
urine	O
and	O
no	B:C0205160
capsular	O
polysaccharide	I:C0982056
accumulation	O
occurs	O
in	O
the	O
major	O
organs	O
.	O

The	O
results	O
indicate	O
that	O
capsular	O
polysaccharide	I:C0982056
is	O
predominantly	O
eliminated	O
through	O
urine	O
and	O
no	O
capsular	B:C0982056
polysaccharide	I:C0982056
accumulation	O
occurs	O
in	O
the	O
major	O
organs	O
.	O

The	O
results	O
indicate	O
that	O
capsular	O
polysaccharide	I:C0982056
is	O
predominantly	O
eliminated	O
through	O
urine	O
and	O
no	O
capsular	O
polysaccharide	I:C0982056
accumulation	B:C4055506
occurs	O
in	O
the	O
major	O
organs	O
.	O

The	O
results	O
indicate	O
that	O
capsular	O
polysaccharide	I:C0982056
is	O
predominantly	O
eliminated	O
through	O
urine	O
and	O
no	O
capsular	O
polysaccharide	I:C0982056
accumulation	O
occurs	O
in	O
the	O
major	O
organs	B:C0178784
.	O

Immunoblot	B:C0020985
analysis	I:C0020985
demonstrated	O
that	O
intact	O
capsular	O
polysaccharide	I:C0982056
was	O
excreted	O
through	O
urine	O
.	O

Immunoblot	O
analysis	I:C0020985
demonstrated	O
that	O
intact	O
capsular	B:C0982056
polysaccharide	I:C0982056
was	O
excreted	O
through	O
urine	O
.	O

Immunoblot	O
analysis	I:C0020985
demonstrated	O
that	O
intact	O
capsular	O
polysaccharide	I:C0982056
was	O
excreted	B:C0221102
through	O
urine	O
.	O

Immunoblot	O
analysis	I:C0020985
demonstrated	O
that	O
intact	O
capsular	O
polysaccharide	I:C0982056
was	O
excreted	O
through	O
urine	B:C0042036
.	O

To	O
understand	B:C0162340
how	O
a	O
large	O
molecule	O
like	O
capsular	O
polysaccharide	I:C0982056
was	O
eliminated	O
without	O
degradation	O
,	O
a	O
3	O
-	I:C0026377
dimenational	I:C0026377
structure	I:C0026377
of	O
capsular	O
polysaccharide	I:C0982056
was	O
modeled	O
.	O

To	O
understand	O
how	O
a	O
large	O
molecule	O
like	O
capsular	B:C0982056
polysaccharide	I:C0982056
was	O
eliminated	O
without	O
degradation	O
,	O
a	O
3	O
-	I:C0026377
dimenational	I:C0026377
structure	I:C0026377
of	O
capsular	O
polysaccharide	I:C0982056
was	O
modeled	O
.	O

To	O
understand	O
how	O
a	O
large	O
molecule	O
like	O
capsular	O
polysaccharide	I:C0982056
was	O
eliminated	O
without	O
degradation	B:C0314674
,	O
a	O
3	O
-	I:C0026377
dimenational	I:C0026377
structure	I:C0026377
of	O
capsular	O
polysaccharide	I:C0982056
was	O
modeled	O
.	O

To	O
understand	O
how	O
a	O
large	O
molecule	O
like	O
capsular	O
polysaccharide	I:C0982056
was	O
eliminated	O
without	O
degradation	O
,	O
a	O
3	B:C0026377
-	I:C0026377
dimenational	I:C0026377
structure	I:C0026377
of	O
capsular	O
polysaccharide	I:C0982056
was	O
modeled	O
.	O

To	O
understand	O
how	O
a	O
large	O
molecule	O
like	O
capsular	O
polysaccharide	I:C0982056
was	O
eliminated	O
without	O
degradation	O
,	O
a	O
3	O
-	I:C0026377
dimenational	I:C0026377
structure	I:C0026377
of	O
capsular	B:C0982056
polysaccharide	I:C0982056
was	O
modeled	O
.	O

The	O
predicted	O
capsular	B:C0982056
polysaccharide	I:C0982056
structure	O
has	O
a	O
rod	O
-	I:C0332479
like	I:C0332479
shape	I:C0332479
with	O
a	O
small	O
diameter	O
that	O
could	O
allow	O
it	O
to	O
flow	O
through	O
the	O
glomerulus	O
of	I:C0022663
the	I:C0022663
kidney	I:C0022663
.	O

The	O
predicted	O
capsular	O
polysaccharide	I:C0982056
structure	B:C0678594
has	O
a	O
rod	O
-	I:C0332479
like	I:C0332479
shape	I:C0332479
with	O
a	O
small	O
diameter	O
that	O
could	O
allow	O
it	O
to	O
flow	O
through	O
the	O
glomerulus	O
of	I:C0022663
the	I:C0022663
kidney	I:C0022663
.	O

The	O
predicted	O
capsular	O
polysaccharide	I:C0982056
structure	O
has	O
a	O
rod	B:C0332479
-	I:C0332479
like	I:C0332479
shape	I:C0332479
with	O
a	O
small	O
diameter	O
that	O
could	O
allow	O
it	O
to	O
flow	O
through	O
the	O
glomerulus	O
of	I:C0022663
the	I:C0022663
kidney	I:C0022663
.	O

The	O
predicted	O
capsular	O
polysaccharide	I:C0982056
structure	O
has	O
a	O
rod	O
-	I:C0332479
like	I:C0332479
shape	I:C0332479
with	O
a	O
small	O
diameter	O
that	O
could	O
allow	O
it	O
to	O
flow	O
through	O
the	O
glomerulus	B:C0022663
of	I:C0022663
the	I:C0022663
kidney	I:C0022663
.	O

capsular	B:C0982056
polysaccharide	I:C0982056
clearance	O
was	O
determined	O
using	O
exponential	O
decay	I:C0430022
models	I:C0430022
and	O
the	O
corrected	O
Akaike	O
Information	O
Criterion	O
.	O

capsular	O
polysaccharide	I:C0982056
clearance	O
was	O
determined	O
using	O
exponential	B:C0430022
decay	I:C0430022
models	I:C0430022
and	O
the	O
corrected	O
Akaike	O
Information	O
Criterion	O
.	O

The	O
results	O
show	O
that	O
capsular	B:C0982056
polysaccharide	I:C0982056
has	O
a	O
relatively	O
short	O
serum	O
half	O
-	O
life	O
of	O
2.9	O
to	O
4.4	O
hours	O
.	O

The	O
results	O
show	O
that	O
capsular	O
polysaccharide	I:C0982056
has	O
a	O
relatively	O
short	O
serum	B:C0229671
half	O
-	O
life	O
of	O
2.9	O
to	O
4.4	O
hours	O
.	O

Therefore	O
,	O
the	O
presence	B:C0150312
of	O
capsular	O
polysaccharide	I:C0982056
in	O
the	O
serum	O
and	O
/	O
or	O
urine	O
suggests	O
active	O
melioidosis	O
infection	I:C0025229
and	O
provides	O
a	O
marker	O
to	O
monitor	O
treatment	I:C0150369
of	O
melioidosis	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
capsular	B:C0982056
polysaccharide	I:C0982056
in	O
the	O
serum	O
and	O
/	O
or	O
urine	O
suggests	O
active	O
melioidosis	O
infection	I:C0025229
and	O
provides	O
a	O
marker	O
to	O
monitor	O
treatment	I:C0150369
of	O
melioidosis	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
capsular	O
polysaccharide	I:C0982056
in	O
the	O
serum	B:C0229671
and	O
/	O
or	O
urine	O
suggests	O
active	O
melioidosis	O
infection	I:C0025229
and	O
provides	O
a	O
marker	O
to	O
monitor	O
treatment	I:C0150369
of	O
melioidosis	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
capsular	O
polysaccharide	I:C0982056
in	O
the	O
serum	O
and	O
/	O
or	O
urine	B:C0042036
suggests	O
active	O
melioidosis	O
infection	I:C0025229
and	O
provides	O
a	O
marker	O
to	O
monitor	O
treatment	I:C0150369
of	O
melioidosis	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
capsular	O
polysaccharide	I:C0982056
in	O
the	O
serum	O
and	O
/	O
or	O
urine	O
suggests	O
active	O
melioidosis	B:C0025229
infection	I:C0025229
and	O
provides	O
a	O
marker	O
to	O
monitor	O
treatment	I:C0150369
of	O
melioidosis	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
capsular	O
polysaccharide	I:C0982056
in	O
the	O
serum	O
and	O
/	O
or	O
urine	O
suggests	O
active	O
melioidosis	O
infection	I:C0025229
and	O
provides	O
a	O
marker	B:C0005516
to	O
monitor	O
treatment	I:C0150369
of	O
melioidosis	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
capsular	O
polysaccharide	I:C0982056
in	O
the	O
serum	O
and	O
/	O
or	O
urine	O
suggests	O
active	O
melioidosis	O
infection	I:C0025229
and	O
provides	O
a	O
marker	O
to	O
monitor	B:C0150369
treatment	I:C0150369
of	O
melioidosis	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
capsular	O
polysaccharide	I:C0982056
in	O
the	O
serum	O
and	O
/	O
or	O
urine	O
suggests	O
active	O
melioidosis	O
infection	I:C0025229
and	O
provides	O
a	O
marker	O
to	O
monitor	O
treatment	I:C0150369
of	O
melioidosis	B:C0025229
.	O

